Zilofung Injection contains Micafungin 50mg, an echinocandin class antifungal agent indicated for the treatment of invasive candidiasis, including candidemia, acute disseminated candidiasis, Candida peritonitis, and abscesses. Micafungin exerts its antifungal activity by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall, leading to cell lysis and death. Zilofung Injection is administered intravenously and is typically reserved for patients who are refractory to or intolerant of other antifungal therapies. It demonstrates potent activity against a broad spectrum of Candida species, including strains resistant to azoles and amphotericin B. The pharmacokinetic profile allows for once-daily dosing, with rapid distribution and hepatic metabolism primarily via arylsulfatase and catechol-O-methyltransferase pathways. Common adverse effects include mild gastrointestinal disturbances, elevated liver enzymes, and infusion-related reactions. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored regularly during therapy. Zilofung Injection should be used under strict medical supervision, ensuring appropriate dosing adjustments based on clinical response and patient-specific factors. Its use contributes significantly to the management of severe fungal infections, improving patient outcomes in immunocompromised and critically ill populations.